Terumo Neuro, a global leader in neurovascular innovation and a wholly-owned subsidiary of Terumo Corporation, proudly celebrates the 15th anniversary of t...
Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned s...
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab), the first and only IL-23...
Novartis announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with ...
Paratek Pharmaceuticals and Optinose, Inc. announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, includ...
Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleas...
Altesa BioSciences, Inc., a clinical-stage pharmaceutical company dedicated to developing new treatments for viral infections in vulnerable populations, an...
Cumberland Pharmaceuticals Inc. a specialty pharmaceutical company with development efforts focused on rare diseases, announced that results from its Phase...
RICHMOND, British Columbia, bioLytical Laboratories Inc. (“bioLytical”), a global leader in rapid infectious disease diagnostics, announces the...
Moon Surgical, a French-American pioneer in surgical innovation, announced the United States Food and Drug Administration (FDA) clearance for ScoPilot. Ena...
Signal12, Inc., a clinical-stage ophthalmic pharmaceutical company focused on first-of-a-kind patented technologies that enable existing drugs to act...
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treat...
Mozart Therapeutics, the leading developer of CD8 Treg modulators for the treatment of autoimmune disease, announce the successful completion of thei...
TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 long-acting dual bNAb regime...
© 2025 Biopharma Boardroom. All Rights Reserved.
